Shutdown bars FDA officials from attending conferences

10/4/2013 | PharmExec.com

The U.S. government shutdown prevented FDA and NIH officials from attending the Drug Information Association's Clinical Trial Disclosure conference in Maryland, and FDA participants had to leave the Regulatory Affairs Professionals Society meeting in Boston, Jill Wechsler writes. The FDA stopped routine drug manufacturing facility inspections and clinical research locations, as well as accepting new regulatory filings that carry fees, she writes. Possible consequences include delays in carrying out programs and issuing documents, as well as missed review deadlines. Many FDA employees may have to be removed from the agendas of upcoming conferences.

View Full Article in:

PharmExec.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park